CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application
– Sugemalimab becomes the world’s first anti-PD-1/PD-L1 monoclonal antibody to successfully improve progression-free survival (PFS) in patients with stage III non-small-cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemoradiotherapy – Sugemalimab is also the world’s first anti-PD-1/PD-L1 monoclonal antibody covering both locally advanced/unresectable (stage III) and metastatic (stage…
